home All News open_in_new Full Article

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st

SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab, in […]



Junshi Biosciences received NMPA approval for its sNDA for toripalimab, in combination with bevacizumab, for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). The approval was based on the HEPATORCH study, which demonstrated improved PFS and OS compared to sorafenib, with a manageable safety profile. This marks the 11th approved indication for toripalimab in China.

today 44 h. ago attach_file Other

attach_file Events
attach_file Other
attach_file Other
attach_file Politics
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Sport
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Other


ID: 985585908
Add Watch Country

arrow_drop_down